3.48
0.20 (6.10%)
| Previous Close | 3.28 |
| Open | 3.27 |
| Volume | 43,142 |
| Avg. Volume (3M) | 584,416 |
| Market Cap | 7,257,063 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.700 |
| Current Ratio (MRQ) | 1.93 |
| Operating Cash Flow (TTM) | -9.37 M |
| Levered Free Cash Flow (TTM) | -4.87 M |
| Return on Assets (TTM) | -106.68% |
| Return on Equity (TTM) | -285.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Acurx Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company’s segment consists of the development of clinical and preclinical product candidates for the development of the Company’s proprietary new therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.95% |
| % Held by Institutions | 18.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prospect Financial Services Llc | 30 Sep 2025 | 19,883 |
| Nbc Securities, Inc. | 30 Sep 2025 | 1,500 |
| Gps Wealth Strategies Group, Llc | 30 Sep 2025 | 1,225 |
| Cornerstone Planning Group Llc | 30 Sep 2025 | 67 |
| 52 Weeks Range | ||
| Median | 31.00 (790.81%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Sep 2025 | 31.00 (790.80%) | Buy | 4.29 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |